Blog
Levels of cell-free DNA do not impact ctDNA detection in patients with CRC
January 2023 There is increasing evidence to support the use of circulating tumour DNA (ctDNA) as a biomarker to detect...
Trifluridine plus tipiracil and bevacizumab is a new standard of care for refractory metastatic colorectal cancer
January 2023 Findings from the phase III SUNLIGHT trial were presented at the 2023 ASCO Gastrointestinal Cancers Symposium, demonstrating that...
The CheckMate 8HW study: A study of nivolumab, nivolumab plus ipilimumab, or investigator’s choice chemotherapy for the treatment of participants with deficient mismatch repair (dMMR) / microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)
Locations: BC, AB, ON, QC Status: currently recruiting Trial description: The purpose of this study is to compare the clinical...
Exercise during chemo may help beat the treatment’s debilitating effects
November 2022 A new study involving patients with different cancer types who were undergoing chemotherapy found that exercising during treatment...
Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients
November 2022 To better understand the role of the gut microbiome in colorectal cancer (CRC) development, a new study investigated...
Diverticular disease associated with increased risk of multiple cancers
October 2022 A recent study published in the Journal of the National Cancer Institute found that patients with diverticular disease...
